Q-Line Biotech Limited

*In cases where losses attributable to minority exceed their equity in the subsidiary, the excess is adjusted against the parent's interest as per AS 21.

5. During the financial year 2024-25, the management of the company has disposed off the investment in POCT Science House Pvt Ltd resulting in change in management of the associate company, accordingly for the purpose of restatement due to no control in associate, therefore restated consolidated financial has been prepared basis of audited financial statements for the FY 2022-23 and 2023-24 and management certified financials for the interim period ended 14th March 2025 which is nearest available financial to the disposal date of investment i.e. 20th March 2025

5. Details of Foreign Exchange earnings, expenditures are as under:-

<table><thead><tr><th rowspan="2">Particulars</th><th colspan="3">For the Year ended on</th></tr><tr><th>31-03-2025</th><th>31-03-2024</th><th>31-03-2023</th></tr></thead><tbody><tr><td colspan="4"><strong>1. CIF Value of Imports</strong></td></tr><tr><td>(a) Raw Material</td><td></td><td></td><td></td></tr><tr><td>In USD-Lakhs</td><td>9.59</td><td>6.31</td><td>4.30</td></tr><tr><td>In Euro-Lakhs</td><td>11.60</td><td>13.78</td><td>4.20</td></tr><tr><td>In GBP-Lakhs</td><td>0.16</td><td>0.24</td><td>0.02</td></tr><tr><td>In JPY-Lakhs</td><td>26.28</td><td>-</td><td>31.10</td></tr><tr><td>In INR- Lakhs</td><td>1,964.65</td><td>1,874.19</td><td>779.89</td></tr><tr><td>(b) Purchases of Stock in Trade</td><td></td><td></td><td></td></tr><tr><td>In USD-Lakhs</td><td>54.66</td><td>85.69</td><td>42.99</td></tr><tr><td>In Euro-Lakhs</td><td>24.41</td><td>32.24</td><td>29.07</td></tr><tr><td>In GBP-Lakhs</td><td>0.09</td><td>0.17</td><td>-</td></tr><tr><td>In SEK-Lakhs</td><td>-</td><td>-</td><td>58.51</td></tr><tr><td>In INR- Lakhs</td><td>7,102.76</td><td>10,503.45</td><td>6,849.53</td></tr><tr><td>(c) Capital Goods/ Stores & Spare Parts</td><td></td><td></td><td></td></tr><tr><td>In USD-Lakhs</td><td>0.06</td><td>3.05</td><td>-</td></tr><tr><td>In Euro-Lakhs</td><td>-</td><td>0.53</td><td>-</td></tr><tr><td>In GBP-Lakhs</td><td>-</td><td>0.00</td><td>-</td></tr><tr><td>In SEK-Lakhs</td><td>-</td><td>1.45</td><td>-</td></tr><tr><td>In INR- Lakhs</td><td>5.43</td><td>329.29</td><td>-</td></tr><tr><td>(d) Technology Fees Glucometer</td><td></td><td></td><td></td></tr><tr><td>In USD-Lakhs</td><td></td><td>0.12</td><td></td></tr><tr><td>In INR- Lakhs</td><td></td><td>10.01</td><td></td></tr><tr><td>(e) Technology Fees PRO M</td><td></td><td></td><td></td></tr><tr><td>In Euro-Lakhs</td><td></td><td>1.31</td><td>0.22</td></tr><tr><td>In INR- Lakhs</td><td></td><td>116.84</td><td>17.79</td></tr><tr><td>(f) Advance Royalty</td><td></td><td></td><td></td></tr><tr><td>In USD-Lakhs</td><td></td><td>6.00</td><td></td></tr><tr><td>In INR- Lakhs</td><td></td><td>498.86</td><td></td></tr><tr><td colspan="4"><strong>2. Expenditure in Foreign Currency</strong></td></tr><tr><td>In respect of Business Promotion, Repair & Maintenance & Profession Consultancy & Other Miscellaneous Expenses</td><td></td><td>-</td><td>-</td></tr><tr><td>In USD-Lakhs</td><td>0.31</td><td>0.27</td><td>0.17</td></tr><tr><td>In INR- Lakhs</td><td>26.28</td><td>22.35</td><td>14.04</td></tr><tr><td>In respect of Royalty</td><td>-</td><td>-</td><td>-</td></tr><tr><td>In USD-Lakhs</td><td>19.92</td><td></td><td></td></tr><tr><td>In EURO-Lakhs</td><td>1.17</td><td></td><td></td></tr><tr><td>In INR- Lakhs</td><td>1,810.47</td><td></td><td></td></tr><tr><td>- In respect of Foreign Travelling.</td><td>-</td><td>-</td><td>-</td></tr><tr><td colspan="4"><strong>3. Earnings in Foreign Currency</strong></td></tr><tr><td>Exports (FOB Value)- In Lakhs- US$</td><td>0.06</td><td>0.16</td><td>0.14</td></tr><tr><td>Exports (FOB Value)- In Lakhs- Euro</td><td>0.33</td><td>0.10</td><td>-</td></tr><tr><td>Exports (FOB Value)- In Lakhs- INR</td><td>35.37</td><td>22.24</td><td>11.47</td></tr></tbody></table>

7. Disclosure Regarding Derivative Instruments And Unhedged Foreign Currency Exposure - There is no outstanding derivative instrument as on the end of respective period/year

<table><thead><tr><th>Disclosure of Unhedged Balances:</th><th>For the Year ended on</th></tr></thead></table>

235